Home › Intelligence › Brief
VULNERABILITY BRIEF 🟠 High Vulnerability

Cleartext Transmission Vulnerability (CVE‑2026‑111594) Exposes Data in InterSystems IRIS for Health

InterSystems IRIS for Health versions 2025‑2026 ship with TLS disabled by default, allowing an attacker to capture credentials and patient data in transit. The issue underscores the need for verifiable encryption controls to satisfy audit and regulatory expectations.

Verisq™ Intelligence · 📅 October 23, 2026 · 📰 cisa.gov
🟠
Severity
High
VU
Type
Vulnerability
🎯
Confidence
High
🏢
Affected
1 sector(s)
✅
Actions
3 recommended
📰
Source
cisa.gov

Critical Cleartext Transmission Vulnerability (CVE‑2026‑111594) in InterSystems IRIS for Health

What It Is — InterSystems IRIS for Health ships with TLS/SSL encryption disabled by default, exposing client‑server traffic to eavesdropping. The flaw (CVE‑2026‑111594) carries a CVSS v3.1 base score of 8.1, classifying it as a high‑severity issue.

Exploitability — No public exploit code is required; any adversary who can observe network traffic can capture clear‑text credentials and patient data. The vulnerability is listed in CISA’s Industrial Control Systems Medical Advisory, indicating active awareness by U.S. authorities.

Affected Products — InterSystems IRIS for Health versions:

  • 2025.3.0.226
  • 2026.1.0.235
  • 2026.2.0.221

Why It Matters for Trust & Control Assurance

  • Shows the necessity of continuous verification that encryption controls are enforced across all health‑IT deployments.
  • Provides audit‑ready evidence that a “protect data in transit” control is operating—a prerequisite for many regulatory frameworks.
  • Highlights the value of automated configuration monitoring to surface mis‑configurations before they become exploitable.

Recommended Actions

  1. Enable TLS/SSL on the IRIS superserver immediately, following InterSystems’ hardening checklist.
  2. Run a configuration scan of every IRIS for Health instance to confirm encryption is active.
  3. Integrate the encryption setting into your continuous control‑monitoring program and retain evidence for audit purposes.

Source: CISA Advisory – ICSMA‑26‑295‑01

📰 Original Source
https://www.cisa.gov/news-events/ics-medical-advisories/icsma-26-295-01 ↗

This Verisq Intelligence Brief is an independent analysis. Read the original reporting at the link above.

Vulnerability exposure

Is this CVE in your supply chain?

Verisq matches published vulnerabilities against the software your vendors run, so you know which relationships this touches before the next review.

See vendor exposure →